Major inter-laboratory variations in PSA testing practices: Results from national surveys in Ireland in 2006 and 2007

Irish Journal of Medical Science

Volumn 177, Issue 4, 2008, Pages 317-323

  Drummond, F J ^a   Sharp, L ^a   Comber, H ^a  

^a NATIONAL CANCER REGISTRY IRELAND   (Ireland)

Author keywords

Laboratory; Prostate cancer; Prostate Specific Antigen; PSA; Screening; Survey

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; DIAGNOSIS, MEASUREMENT AND ANALYSIS; GENERAL PRACTITIONER; HUMAN; INFORMATION PROCESSING; IRELAND; MALE; MASS SCREENING; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; QUESTIONNAIRE; STANDARD; STATISTICS; UROLOGY; WORKLOAD;

ADULT; AGED; DATA COLLECTION; HUMANS; IRELAND; LABORATORY TECHNIQUES AND PROCEDURES; MALE; MASS SCREENING; MIDDLE AGED; PHYSICIANS, FAMILY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUESTIONNAIRES; UROLOGY; WORKLOAD;

EID: 61749086905     PISSN: 00211265     EISSN: 18634362     Source Type: Journal    
DOI: 10.1007/s11845-008-0216-1     Document Type: Article

References (31)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108
2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18:581-592. doi:10.1093/annonc/mdl498
3. National Cancer Registry Ireland. www.ncri.ie
4. Drummond FJ, Sharp L, Carsin A-E, Deady S, Comber H (2007) PSA testing and prostate cancer diagnosis in the Republic of Ireland. BJU Int 100(Suppl):3;23
5. UK National Screening Committee (1998) First report of the National Screening Committee. London: Department of health, 1998. www.nsc.nhs.uk/pdfs/ nsc-firstreport.pdf
6. The National Cancer Forum a strategy for Cancer Control in Ireland (2006) www.dohc.ie/publications/pdf/en-cancer-control-2006.pdf
7. Drummond FJ, Sharp L, Carsin AE, Kelleher T, Comber H (2008) Questionnaire order significantly increased response to a postal survey sent to primary care physicians. J Clin Epidemiol 61:177-185. doi:10.1016/j.jclinepi. 2007.04.012
8. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA et al (1993) Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 270:860-864. doi:10.1001/jama.270.7.860
9. Association of Clinical Biochemists in Ireland (ACBI) guidelines. http://www.acbi.ie/
10. Määttänen L, Auvinen A, Stenman UH, Tammela T, Rannikko S, Aro J et al (2001) Three-year results of the Finnish prostate cancer screening trial. J Natl Cancer Inst 93:552-553. doi:10. 1093/jnci/93.7.552
11. Ilic D, O'Connor D, Green S, Wilt T (2006) Screening for prostate cancer. Cochrane Database Syst Rev 3:CD004720
12. Onur R, Ilhan N, Orhan I, Ilhan N (2003) Increased discrimination between benign prostatic hyperplasia and prostate cancer with equimolar total prostate specific antigen measurement. World J Urol 21(1):43-47
13. Roddam AW, Price CP, Allen NE, Ward AM (2004) Assessing the clinical impact of prostate-specific antigen assay variability and nonequimolarity: a simulation study based on the population of the United Kingdom. Clin Chem 50(6):1012-1016. doi: 10.1373/clinchem.2004.031138
14. Patel D, White PA, Milford Ward A (2000) A comparison of six commercial assays for total and free prostate specific antigen (PSA): the predictive value of the ratio of free to total PSA. BJU Int 85(6):686-689. doi:10.1046/j.1464- 410x.2000.00526.x
15. Bock JL, Klee GG (2004) How sensitive is a prostate-specific antigen measurement? How sensitive does it need to be? Arch Pathol Lab Med 128:341-343
16. Mistry K, Cable G (2003) Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Pract 16:95-101
17. Zhu H, Roehl KA, Antenor JA, Catalona WJ (2005) Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis. Urology 66:547-551. doi:10.1016/j.urology. 2005.03.093
18. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A et al (1998) Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279:1542-1547. doi:10.1001/jama.279.19.1542
19. Catalona WJ, Partin AW, Finlay JA, Chan DW, Rittenhouse HG, Wolfert RL et al (1999) Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology 54:220-224. doi:10.1016/S0090-4295(99)00185-5
20. Chun FK, Hutterer GC, Perrotte P, Gallina A, Valiquette L, Benard F et al (2007) Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer. BJU Int 100(1):37 doi:10.1111/j.1464-410X.2007.06923.x
21. All Ireland Cancer Statistics 1998-2000. http://www.ncri.ie/pubs/pubs. shtml
22. Sokoll LJ, Bruzek DJ, Dua R, Dunn W, Mohr P, Wallerson G et al (2002) Short-term stability of the molecular forms of prostate- specific antigen and effect on percent complexed prostatespecific antigen and percent free prostate-specific antigen. Urology 60((4)(Suppl 1)):24-30. doi:10.1016/S0090- 4295(02) 01723-5
23. Cartledge JJ, Thompson D, Verril H, Clarkson P, Eardley I (1999) The stability of free and bound prostate-specific antigen. BJU Int 84(7):810-814. doi:10.1046/j.1464-410x.1999.00311.x
24. Drummond FJ, Comber H (2007) PSA testing-weighing up the evidence. Forum. Clin Focus 7:15-18
25. Irish Cancer Society Action Prostate Cancer. http://www.cancer.ie/ prostate
26. McGing PG (1998) A study of PSA requests from general practitioners received by one Dublin hospital. Ir Med J 91:61-62
27. http://www.dohc.ie/press/releases/2006/20060612.html
28. Gavin A, McCarron P, Middleton RJ, Savage G, Catney D, O'Reilly D et al (2004) Evidence of prostate cancer screening in a UK region. BJU Int 93:730-734. doi:10.1111/j.1464-410X. 2003.04716.x
29. Colditz GA, Emmons KM, Vishwanath K, Kerner JF (2008) Translating science to practice: community and academic perspectives. J Public Health Manag Pract 14:144-149
30. Kerner JF (2008) Integrating research, practice, and policy: what we see depends on where we stand. J Public Health Manag Pract 14:193-198
31. Connolly D, Black A, Gavin A, Keane PF, Murray LJ (2008) Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation. Cancer Epidemiol Biomarkers Prev 17:271-278. doi:10.1158/1055- 9965.EPI-07-0515